share_log

Healthcare Services Group, Inc. Just Beat EPS By 38%: Here's What Analysts Think Will Happen Next

Healthcare Services Group, Inc. Just Beat EPS By 38%: Here's What Analysts Think Will Happen Next

醫療服務集團公司剛剛超過每股收益38%:分析師認爲接下來會發生什麼
Simply Wall St ·  02/17 07:31

Shareholders will be ecstatic, with their stake up 29% over the past week following Healthcare Services Group, Inc.'s (NASDAQ:HCSG) latest full-year results. It looks like a credible result overall - although revenues of US$1.7b were what the analysts expected, Healthcare Services Group surprised by delivering a (statutory) profit of US$0.52 per share, an impressive 38% above what was forecast. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

股東們將欣喜若狂,繼醫療服務集團之後,他們的股份在過去一週上漲了29%。”s(納斯達克股票代碼:HCSG)最新的全年業績。總體而言,這似乎是一個可信的業績——儘管分析師預期的收入爲17億美元,但醫療保健服務集團卻驚訝地實現了每股0.52美元的(法定)利潤,比預期高出38%。分析師通常會在每份收益報告中更新他們的預測,我們可以從他們的估計中判斷他們對公司的看法是否發生了變化,或者是否有任何新的問題需要注意。因此,我們收集了最新的業績後法定共識估計,以了解明年可能會發生什麼。

earnings-and-revenue-growth
NasdaqGS:HCSG Earnings and Revenue Growth February 17th 2024
納斯達克GS:HCSG收益和收入增長 2024年2月17日

Taking into account the latest results, the most recent consensus for Healthcare Services Group from four analysts is for revenues of US$1.73b in 2024. If met, it would imply a credible 3.5% increase on its revenue over the past 12 months. Per-share earnings are expected to bounce 52% to US$0.79. In the lead-up to this report, the analysts had been modelling revenues of US$1.74b and earnings per share (EPS) of US$0.73 in 2024. The analysts seems to have become more bullish on the business, judging by their new earnings per share estimates.

考慮到最新業績,四位分析師對醫療服務集團的最新共識是,2024年的收入爲17.3億美元。如果得到滿足,這意味着其收入在過去12個月中可信地增長了3.5%。每股收益預計將反彈52%,至0.79美元。在本報告發布之前,分析師一直在模擬2024年的收入爲17.4億美元,每股收益(EPS)爲0.73美元。從他們新的每股收益估計來看,分析師似乎對該業務變得更加看好。

The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 14% to US$14.50. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Healthcare Services Group analyst has a price target of US$17.00 per share, while the most pessimistic values it at US$13.00. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

在收益上調的背景下,分析師一直在提高目標股價,共識目標股價上漲了14%,至14.50美元。研究分析師的估計範圍,評估異常值與平均值的差異程度也可能很有啓發性。最樂觀的醫療服務集團分析師將目標股價定爲每股17.00美元,而最悲觀的分析師則將其估值爲13.00美元。由於估值範圍如此狹窄,分析師顯然對他們認爲的業務價值有相似的看法。

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that Healthcare Services Group is forecast to grow faster in the future than it has in the past, with revenues expected to display 3.5% annualised growth until the end of 2024. If achieved, this would be a much better result than the 3.6% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 6.8% per year. Although Healthcare Services Group's revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry.

我們可以從大局的角度看待這些估計值的另一種方式,例如預測如何與過去的表現相提並論,以及預測相對於業內其他公司是否或多或少看漲。從這些估計中可以看出一件事,那就是預計醫療服務集團未來的增長速度將比過去更快,預計到2024年底,收入將實現3.5%的年化增長。如果實現,這將比過去五年3.6%的年下降幅度好得多。相比之下,我們的數據表明,預計類似行業的其他公司(有分析師報道)的收入每年將增長6.8%。儘管預計醫療服務集團的收入將有所改善,但分析師似乎仍然看跌該業務,預計該業務的增長將低於整個行業。

The Bottom Line

底線

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Healthcare Services Group following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.

這裏最重要的是,分析師上調了每股收益預期,這表明在這些業績公佈後,對醫療保健服務集團的樂觀情緒明顯增強。從好的方面來看,收入估計沒有重大變化;儘管預測表明它們的表現將比整個行業差。目標股價也大幅提高,分析師顯然認爲該業務的內在價值正在提高。

Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have forecasts for Healthcare Services Group going out to 2026, and you can see them free on our platform here.

根據這種思路,我們認爲該業務的長期前景比明年的收益重要得多。我們對醫療服務集團到2026年的發展做出了預測,你可以在我們的平台上免費查看。

Another thing to consider is whether management and directors have been buying or selling stock recently. We provide an overview of all open market stock trades for the last twelve months on our platform, here.

需要考慮的另一件事是管理層和董事最近是否在買入或賣出股票。我們在此處概述了過去十二個月在我們的平台上所有公開市場股票交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論